Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Background No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor 1,5 modulator, on disability progression in patients with SPMS. Methods This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18-60 years) with SPMS and an Expanded Disability Status Scale score of 3·0-6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time sin…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While disease-modifying therapies have significantly improved prognosis for relapsing forms of multiple sclerosis (RMS), effective treatments for the progressive, neurodegenerative phase are lacking.”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [19]
In the citing paper
“Most DMTs are approved for treatment of relapsing MS (RMS) [17], a smaller number have shown benefit in some SPMS populations [19, 22, 23], but only one DMT has shown efficacy for treatment of PPMS, underlining the unmet need of treatment options for these patients [20] (Table 2).”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [19]
In the citing paper
“However, while several DMTs reduce inflammatory activity and can slow disability accumulation in some progressive MS populations, progression and neurodegeneration remain important unmet needs [19–21].”
From Insights and challenges on animal models for progressive multiple sclerosis (2026) · cites this paper as [19]
In the citing paper
“In MS only siponimod, an S1P1/S1P5 receptor modulator, which is not currently licensed, has shown a modest effect in a phase III trial (EXPAND) in secondary- progressive MS, preventing disability progression by 21% in two years [294].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [294]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationA Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationMultiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963
Self-citationKappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Self-citationBrinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438
Research works printed but not linked: 2
- Steiner, 2016, Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial, Neurology, 86, E22
- Aslanis, 2012, Siponimod (BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter areas, Mult Scler, 18, 279
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Self-citationMultiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Self-citationFunction and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Metadata
- Authors
- Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., Wolf, C., Wallström, E., Dahlke, F., Achiron, A., Achtnichts, L., Agan, K., Akman-Demir, G., Allen, A. B., Antel, J. P., Antiguedad, A. R., Apperson, M., Applebee, A. M., Ayuso, G. I., Baba, M., Bajenaru, O., Balasa, R., Balci, B. P., Barnett, M., Bass, A., Becker, V. U., Bejinariu, M., Bergh, F. T., Bergmann, A., Bernitsas, E., Berthele, A., Bhan, V., Bischof, F., Bjork, R. J., Blevins, G., Boehringer, M., Boerner, T., Bonek, R., Bowen, J. D., Bowling, A., Boyko, A. N., Boz, C., Bracknies, V., Braune, S., Brescia Morra, V., Brochet, B., Brola, W., Brownstone, P. K., Brozman, M., Brunet, D., Buraga, I., Burnett, M., Buttmann, M., Butzkueven, H., Cahill, J., Calkwood, J. C., Camu, W., Cascione, M., Castelnovo, G., Centonze, D., Cerqueira, J., Chan, A., Cimprichova, A., Cohan, S., Comi, G., Conway, J., Cooper, J. A., Corboy, J., Correale, J., Costell, B., Cottrell, D. A., Coyle, P. K., Craner, M., Cui, L., Cunha, L., Czlonkowska, A., da Silva, A. M., de Sa, J., de Seze, J., Debouverie, M., Debruyne, J., Decoo, D., Defer, G., Derfuss, T., Deri, N. H., Dihenia, B., Dioszeghy, P., Donath, V., Dubois, B., Duddy, M., Duquette, P., Edan, G., Efendi, H., Elias, S., Emrich, P. J., Estruch, B. C., Evdoshenko, E. P., Faiss, J., Fedyanin, A. S., Feneberg, W., Fermont, J., Fernandez, O. F., Ferrer, F. C., Fink, K., Ford, H., Ford, C., Francia, A., Freedman, M., Frishberg, B., Galgani, S., Garmany, G. P., Gehring, K., Gitt, J., Gobbi, C., Goldstick, L. P., Gonzalez, R. A., Grandmaison, F., Grigoriadis, N., Grigorova, O., Grimaldi, L. M. E., Gross, J., Gross-Paju, K., Gudesblatt, M., Guillaume, D., Haas, J., Hancinova, V., Hancu, A., Hardiman, O., Harmjanz, A., Heidenreich, F. R., Hengstman, G. J. D., Herbert, J., Herring, M., Hodgkinson, S., Hoffmann, O. M., Hofmann, W. E., Honeycutt, W. D., Hua, L. H., Huang, D., Huang, Y., Huang, D., Hupperts, R., Imre, P., Jacobs, A. K., Jakab, G., Jasinska, E., Kaida, K., Kalnina, J., Kaprelyan, A., Karelis, G., Karussis, D., Katz, A., Khabirov, F. A., Khatri, B., Kimura, T., Kister, I., Kizlaitiene, R., Klimova, E., Koehler, J., Komatineni, A., Kornhuber, A., Kovacs, K., Koves, A., Kozubski, W., Krastev, G., Krupp, L. B., Kurca, E., Lassek, C., Laureys, G., Lee, L., Lensch, E., Leutmezer, F., Li, H., Linker, R. A., Linnebank, M., Liskova, P., Llanera, C., Lu, J., Lutterotti, A., Lycke, J., Macdonell, R., Maciejowski, M., Maeurer, M., Magzhanov, R. V., Maida, E.-M., Malciene, L., Mao-Draayer, Y., Marfia, G. A., Markowitz, C., Mastorodimos, V., Matyas, K., Meca-Lallana, J., Merino, J. A. G., Mihetiu, I. G., Milanov, I., Miller, A. E., Millers, A., Mirabella, M., Mizuno, M., Montalban, X., Montoya, L., Mori, M., Mueller, S., Nakahara, J., Nakatsuji, Y., Newsome, S., Nicholas, R., Nielsen, A. S., Nikfekr, E., Nocentini, U., Nohara, C., Nomura, K., Odinak, M. M., Olsson, T., van Oosten, B. W., Oreja-Guevara, C., Oschmann, P., Overell, J., Pachner, A., Panczel, G., Pandolfo, M., Papeix, C., Patrucco, L., Pelletier, J., Piedrabuena, R., Pless, M., Polzer, U., Pozsegovits, K., Rastenyte, D., Rauer, S., Reifschneider, G., Rey, R., Rizvi, S. A., Robertson, D., Rodriguez, J. M., Rog, D., Roshanisefat, H., Rowe, V., Rozsa, C., Rubin, S., Rusek, S., Saccà, F., Saida, T., Salgado, A. V., Sanchez, V. E. F., Sanders, K., Satori, M., Sazonov, D. V., Scarpini, E. A., Schlegel, E., Schluep, M., Schmidt, S., Scholz, E., Schrijver, H. M., Schwab, M., Schwartz, R., Scott, J., Selmaj, K., Shafer, S., Sharrack, B., Shchukin, I. A., Shimizu, Y., Shotekov, P., Siever, A., Sigel, K.-O., Silliman, S., Simo, M., Simu, M., Sinay, V., Siquier, A. E., Siva, A., Skoda, O., Solomon, A., Stangel, M., Stefoski, D., Steingo, B., Stolyarov, I. D., Stourac, P., Strassburger-Krogias, K., Strauss, E., Stuve, O., Tarnev, I., Tavernarakis, A., Tello, C. R., Terzi, M., Ticha, V., Ticmeanu, M., Tiel-Wilck, K., Toomsoo, T., Tubridy, N., Tullman, M. J., Tumani, H., Turcani, P., Turner, B., Uccelli, A., Urtaza, F. J. O., Vachova, M., Valikovics, A., Walter, S., Van Wijmeersch, B., Vanopdenbosch, L., Weber, J. R., Weiss, S., Weissert, R., Vermersch, P., West, T., Wiendl, H., Wiertlewski, S., Wildemann, B., Willekens, B., Visser, L. H., Vorobeychik, G., Xu, X., Yamamura, T., Yang, Y. N., Yelamos, S. M., Yeung, M., Zacharias, A., Zelkowitz, M., Zettl, U., Zhang, M., Zhou, H., Zieman, U., & Ziemssen, T.
- Affiliations
- University of Basel (CH)
- University of California, San Francisco (US)
- Cleveland Clinic (US)
- Queen Mary University of London (GB)
- St. Josef-Hospital (DE)
- NeuroRx Research (Canada) (CA)
- Novartis (Switzerland) (CH)
- Inserm (FR)
- Centre de Résonance Magnétique Biologique et Médicale (FR)
- Corresponding author
- Kappos, Ludwig
- ORCID
- Kappos, Ludwig
- Cree, Bruce A C
- Fox, Robert J
- Giovannoni, Gavin
- Gold, Ralf
- Arnold, Douglas L
- Wolf, Christian
- Dahlke, Frank
- Achiron, Anat
- Achtnichts, Lutz
- Antel, Jack P
- Baba, Masayuki
- Barnett, Michael
- Bergh, Florian Then
- Bernitsas, Evanthia
- Berthele, Achim
- Bhan, Virender
- Blevins, Gregg
- Bonek, Robert
- Bowen, James D
- Boz, Cavit
- Braune, Stefan
- Brochet, Bruno
- Brola, Waldemar
- Brozman, Miroslav
- Buraga, Ioan
- Buttmann, Mathias
- Butzkueven, Helmut
- Camu, William
- Centonze, Diego
- Chan, Andrew
- Cohan, Stanley
- Comi, Giancarlo
- Corboy, John
- Correale, Jorge
- Coyle, Patricia K
- Cui, Liying
- Debouverie, Marc
- Decoo, Danny
- Defer, Gilles
- Derfuss, Tobias
- Duddy, Martin
- Duquette, Pierre
- Edan, Gilles
- Evdoshenko, Evgeniy P
- Fink, Katharina
- Ford, Helen
- Francia, Ada
- Gobbi, Claudio
- Grigoriadis, Nikolaos
- Grigorova, Olga
- Gudesblatt, Mark
- Hardiman, Orla
- Herbert, Joseph
- Hodgkinson, Suzanne
- Honeycutt, William D
- Hua, Le Hanh
- Huang, Dehui
- Huang, Yining
- Hupperts, Raymond
- Kaida, Kenichi
- Kaprelyan, Ara
- Karelis, Guntis
- Karussis, Dimitrios
- Khatri, Bhupendra
- Kimura, Takashi
- Kister, Ilya
- Kozubski, Wojciech
- Krastev, Georgi
- Krupp, Lauren B
- Laureys, Guy
- Leutmezer, Fritz
- Linker, Ralf A
- Lu, Jiahong
- Lutterotti, Andreas
- Lycke, Jan
- Macdonell, Richard
- Magzhanov, Rim V
- Marfia, Girolama Alessandra
- Markowitz, Clyde
- Meca-Lallana, Jose
- Milanov, Ivan
- Miller, Aaron E
- Mizuno, Masanori
- Mori, Masahiro
- Mueller, Stefanie
- Nakahara, Jin
- Nakatsuji, Yuji
- Newsome, Scott
- Nicholas, Richard
- Nocentini, Ugo
- Odinak, Miroslav M
- Olsson, Tomas
- van Oosten, B W
- Oschmann, Patrick
- Overell, James
- Pachner, Andrew
- Pandolfo, Massimo
- Papeix, Caroline
- Patrucco, Liliana
- Pelletier, Jean
- Pless, Misha
- Rauer, Sebastian
- Rey, Roberto
- Rizvi, Syed A
- Robertson, Derrick
- Rog, David
- Roshanisefat, Homayoun
- Saccà, Francesco
- Sazonov, Denis V
- Scarpini, Elio Angelo
- Schmidt, Stephan
- Schwab, Matthias
- Selmaj, Krzysztof
- Sharrack, Basil
- Shimizu, Yuko
- Simu, Mihaela
- Sinay, Vladimiro
- Solomon, Andrew
- Stangel, Martin
- Stolyarov, Igor D
- Tavernarakis, Antonios
- Terzi, Murat
- Toomsoo, Toomas
- Tumani, Hayrettin
- Uccelli, Antonio
- Walter, Silke
- Vanopdenbosch, Ludo
- Weissert, Robert
- Wiendl, Heinz
- Wildemann, Brigitte
- Willekens, Barbara
- Visser, L H
- Vorobeychik, Galina
- Xu, Xianhao
- Yamamura, Takashi
- Yang, Yi N
- Zettl, Uwe
- Zhou, Hongyu
- Ziemssen, Tjalf
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 391
- Issue
- 10127
- Pages
- 1263-1273
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2790816436
- Cited by
- 942
- References
- 24
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 118 · 2023: 114 · 2022: 137 · 2021: 144 · 2020: 138 · 2019: 96 · 2018: 40
- FWCI
- 79.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- siponimod, secondary progressive multiple sclerosis, confirmed disability progression, disease-modifying therapy, Expanded Disability Status Scale, relapse rate, adverse events, EXPAND trial, treatment efficacy and safety, gait assistance, relapse rate reduction, treatment discontinuation, immunosuppression, immunomodulation
- MeSH terms
- Adolescent, Adult, Azetidines, Benzyl Compounds, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Cohort Studies, Treatment Outcome, Disease Progression, Multiple Sclerosis, Chronic Progressive, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(18)30475-6
- The paper
- Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., Wolf, C., Wallström, E., Dahlke, F., Achiron, A., Achtnichts, L., Agan, K., Akman-Demir, G., Allen, A. B., Antel, J. P., . . . Ziemssen, T. (2018). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(18)30475-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.